samedan logo
 
 
 
spacer
home > pmps > spring 2009 > big pharma, 'little' delivery
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Big Pharma, 'Little' Delivery

Historically, delivery technologies have been a small tactical afterthought compared to the strategic importance placed on the active molecules, but this is now changing. With ‘open innovation’ becoming a corporate mantra, it is important to consider whether the delivery technologies available for licensing and external collaboration can actually help drug- and device-makers reach their strategic goals. There is a surprising amount of venture investment in delivery technologies, as well as a growing number of partnerships, and a healthy ecosystem of innovative startups. Targeted delivery is poised to become a major feature of nearly all new pharmaceutical products, as delivery-dependent biologics, combination products, and personalised medicine rise in strategic importance. Not only are targeted delivery technologies themselves no longer a tactical afterthought, but the small innovators developing them are becoming a key component of larger life science companies’ success as well.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Mark Bünger leads Lux Research’s biosciences intelligence practice, covering targeted delivery, synthetic biology and other emerging fields. He has 18 years of business strategy experience as a management consultant and technology analyst, and has advised more than 40 Fortune 500 corporations, led hundreds of engagements, and authored over 60 reports and other publications. Mark’s works have figured in leading media outlets in the US and Europe, including CNN, PBS, CNBC, NPR, The Wall Street Journal, Financial Times, and other technical, regional and trade publications and channels.

spacer
Mark Bünger
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Merck to Provide BioReliance® End-to-End Solutions to Phanes Therapeutics

• Collaboration to accelerate development and manufacturing of Bispecific Antibody • Merck plans to offer Phanes a full suite of products and services under its BioReliance® offering
More info >>

White Papers

Optimize your Biologic’s Analytical Program for Greater Risk Reduction

Merck

Analytical methods are used throughout upstream and downstream processes to help ensure the desired molecule is being produced with the desired purity. In addition to having the right molecule, quality must be confirmed in terms of glycosylation, oxidation, aggregates, activity and concentration. The analytical package must also ensure that all impurities from the manufacturing process and environment are consistently removed.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement